Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum

Journal of Pharmacological Sciences

Volumn 101, Issue 4, 2006, Pages 286-292

  Adachi, Kouichi ^a   Miwa, Hideto ^a   Kusumoto, Haruko ^b   Shimazu, Seiichiro ^b   Kondo, Tomoyoshi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Fujimoto Pharmaceutical Corporation   (Japan)

Author keywords

Dopamine; L DOPA; Microdialysis; Parkinson's disease; Selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CARBIDOPA; DOPAMINE; LEVODOPA; SELEGILINE;

ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG INHIBITION; MALE; MICRODIALYSIS; NONHUMAN; RAT;

EID: 33747816154     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0051085     Document Type: Article

References (23)

1. Parkinson study group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
2. + in vivo. Eur J Pharmacol. 1993;243:241-247.
3. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehydes-3-phosphate dehydrogenase to a dimer. Mol Pharmacol. 2000;57:2-12.
4. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24:675-682.
5. Andoh T, Chock PB, Murphy DL, Chiueh CC. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol Pharmacol. 2005;68:1408-1414.
6. Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977;1:439-443.
7. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm. 1985;64:113-127.
8. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245:519-522.
9. Themann C, Alvarez Fischer D, Gross S, Westermann R, Weihe E, Kuschinsky K, et al. Effect of repeated treatment with high doses of selegiline on behavior, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:22-28.
10. Hollan S, Vecsei L, Magyar K. Adverse effects of dopamine potentiation by long-term treatment with selegiline. Mov Disord. 2004;19:107-109.
11. Kamakura K, Mochizuki H, Kaida K, Hirata A, Kanzaki M, Masaki T, et al. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline. Parkinsonism Relat Disord. 2004;10:235-242.
12. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm. 2004;111:1447-1453.
13. Brannan T, Prikhojan A, Martinez-Tica J, Yahr MD. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J Neural Transm Park Dis Dement Sect. 1995;10:79-89.
14. Kaseda S, Nomoto M, Iwata S. Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res. 1999;815:44-55.
15. Fornai F, Chen K, Giorgi FS, Gesi M, Alessandri MG., Shih JC. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study. J Neurochem. 1999;73:2434-2440.
16. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. San Diego: Academic Press;1986.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
18. Deng Y, Yu PH. Assessment of the deamination of amino-acetone, an endogenous substrate for semicarbazide-sensitive amine oxidase. Anal Biochem. 1999;270:97-102.
19. Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1989;126:103-111.
20. Bull DR, Sheehan MJ. Presynaptic regulation of electrically evoked dopamine overflow in nucleus accumbens: a pharmacological study using fast cyclic voltammetry in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1991;343:260-265.
21. Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther. 1995;275:899-913.
22. Jonkers N, Sarre S, Ebinger G, Michotte Y. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 2002;926:149-155.
23. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems which the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990;13:272-276.